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Autophagy constitutes amechanism for the sequestration and lysosomal degradation of various cytoplasmic
structures, including damaged organelles and invading microorganisms. Autophagy not only represents an
essential cell-intrinsic mechanism to protect against internal and external stress conditions but also shapes
cellular immunity. Recent evidence indicates that autophagic responses in antigen-donor cells affect the
release of several cytokines and ‘‘danger signals.’’ Thus, especially when it precedes cell death, autophagy
alerts innate immune effectors to elicit cognate immune responses. Autophagy is also important for the dif-
ferentiation, survival, and activation of myeloid and lymphoid cells. Accordingly, inherited mutations in auto-
phagy-relevant genes are associated with immune diseases, whereas oncogenesis-associated autophagic
defects promote the escape of developing tumors from immunosurveillance. Here, we discuss the regulation
of autophagy in the course of cellular immune responses and emphasize its impact on the immunogenicity of
antigen-donor cells and on the activity of antigen-presenting cells and T lymphocytes.Introduction
Macroautophagy (hereafter referred to as ‘‘autophagy’’) initiates
with the sequestration of organelles or portions of the cytoplasm
within double-membraned vesicles, so-called autophago-
somes. Autophagosomes then fuse with lysosomes to generate
autolysosomes, and their luminal content is degraded (Mizush-
ima et al., 2011; Yang and Klionsky, 2010). Autophagy repre-
sents a phylogenetically ancient response that was first
dissected at the genetic level in unicellular eukaryotes (notably
yeast) and was later found to be important in the adaptation of
cells to endogenous and exogenous stress (Kroemer et al.,
2010; Levine and Kroemer, 2008).
Autophagy not only preserves cellular homeostasis in
conditions of endogenous distress (Kroemer et al., 2010) but
also plays a primordial role in controlling intracellular path-
ogens in evolutionarily distant species, ranging from unicel-
lular organisms to humans (Levine et al., 2011). Thus, together
with the endoplasmic reticulum (ER) stress response,
autophagy represents one of the most primitive examples of
innate immune responses. In animals, this cell-autonomous
defense mechanism also facilitates the recognition of infected
cells by innate immune effectors, especially when infection
leads to cell death (Galluzzi et al., 2008a), setting off an elabo-
rate inflammatory or immune response. The importance of
autophagy in the host defense against infection is under-
scored by the fact that bacteria and viruses have developed
a myriad of strategies for subverting or harnessing the autopha-
gic machinery. The complex crosstalk between host and
microbe and their intimate coevolution are reviewed elsewhere
(Kuballa et al., 2012; Levine et al., 2011) and will not be dis-
cussed here.Accumulating evidence suggests that autophagy influences
cellular immune responses well beyond its role as a cell-intrinsic
mechanism of defense against invading pathogens. In particular,
autophagy has recently been shown to influence not only the
antigenic profile of antigen-donor cells (ADCs) and their ability
to release immunogenic signals (Caron et al., 2011; Michaud
et al., 2011) but also the survival, differentiation, and function
of antigen-presenting cells (APCs) and T lymphocytes (Fiegl
et al., 2013; Jia and He, 2011; Pua et al., 2007; Wildenberg
et al., 2012). Here, we discuss the host-intrinsic regulation of
autophagy in the course of cellular immune responses and
examine how autophagy impacts (1) ADCs, whose phenotypic
and/or behavioral features are modified upon infection or onco-
genic mutations; (2) APCs, mainly dendritic cells (DCs), which
capture antigens from ADCs and present antigenic peptides in
complex with MHC molecules on their own surface; and (3) T
lymphocytes, which upon activation by APCs finally attack in-
fected or transformed cells in an antigen-restricted fashion.
The pathophysiological implications of autophagy in this context
are discussed.
Autophagy: A General Stress Response
Constitutive autophagy is required for cellular "housekeeping,"
for example to eliminate occasionally damaged organelles
such as depolarized mitochondria that cannot rejoin the mito-
chondrial network (Green et al., 2011). In addition, autophagy
is upregulated when cells are confronted with potentially
dangerous environmental cues, be they physical (thermal stress,
irradiation) (Apel et al., 2008), chemical (changes in pH, osmolar-
ity) (Xu et al., 2011), ormetabolic (shortage in nutrients or oxygen)
(Boya et al., 2005) and thus constitutes an almost universalImmunity 39, August 22, 2013 ª2013 Elsevier Inc. 211
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autophagic pathway starts with the formation of an isolation
membrane (also known as a phagophore), most often at contact
sites between mitochondria and the endoplasmic reticulum (ER)
(Hamasaki et al., 2013), although other sources of autophagic
membranes have been reported (Ravikumar et al., 2010). Auto-
phagy involves multiple molecular components, including (1)
the unc-51-like kinase 1 (ULK1) complex, which is coupled to
the autophagy suppressor TOR complex 1 (TORC1) (Egan
et al., 2011); (2) the Beclin 1 (BECN1)/class III phosphoinosi-
tide-3-kinase (PI3K) complex, which is usually inhibited by inter-
actions with proteins of the Golgi apparatus, antiapoptotic
proteins of the BCL-2 family, and other signal transducers (He
and Levine, 2010); (3) two transmembrane proteins, ATG9 and
vacuole membrane protein 1 (VMP1) (Molejon et al., 2013; Re-
ggiori and Klionsky, 2006); (4) two ubiquitin-like conjugation sys-
tems, operating on ATG12 andmicrotubule-associated protein 1
light chain 3 (MAP1LC3, the mammalian homolog of yeast Atg8,
best known as LC3) (Mizushima et al., 1998); (5) several proteins
that mediate the fusion between autophagosomes and lyso-
somes (Tumbarello et al., 2012); and (6) a large panel of lyso-
somal hydrolases, which digest proteins, lipids, and nucleic
acids in an acidic microenvironment (Kroemer and Ja¨a¨ttela¨,
2005). Thesemolecular systems drive autophagy only when acti-
vated in a highly coordinated manner and are directly connected
to cell-intrinsic stress-response mechanisms (Kroemer et al.,
2010; Mizushima et al., 2011; Yang and Klionsky, 2010).
Autophagy might occur as a general response during which
distinct portions of the cytoplasm are sequestered and digested
in an apparently nonspecific fashion. The autophagic response
of eukaryotic cells to amino acid deprivation is viewed as a
case of general autophagy, although accumulating evidence
challenges this model (Dengjel et al., 2008; Gomes et al.,
2011). Alternatively, autophagy might target specific portions
of the cytoplasm that are marked for destruction, generally by
ubiquitination. Under specific circumstances, a series of ubiqui-
tinases covalently add to cellular structures K63-linked ubiquitin
chains, which are bound by various adaptors containing an LC3-
interacting region (LIR) and hence are recruited to closing auto-
phagosomes (Fimia et al., 2013; vanWijk et al., 2012). According
to this principle, distinct organelles or intracellular entities (e.g.,
mitochondria, ER, peroxisomes, ribosomes, protein aggregates)
can be selectively targeted for autophagic destruction, resulting
in organelle-specific instances of autophagy that are referred to
as "mitophagy," "reticulophagy," "pexophagy," "ribophagy," or
"aggrephagy," for example.
General and organelle-specific cases of autophagy are stimu-
lated by demand and supply, respectively. The demand for auto-
phagic turnover is increased, for example, by (1) activation of
sensors, such as sirtuin 1, AMP-activated protein kinase
(AMPK), and mammalian target of rapamycin (mTOR), that
respond to a reduction in nutrient availability, (2) activation of
stress-responsive kinases, including c-Jun N-terminal kinase 1
(JNK1); protein kinase, RNA-activated (PKR); PKR-like ER kinase
(PERK); TGF-b-activated kinase 1 (TAK1); death-associated pro-
tein kinase 1 (DAPK1); and the inhibitor of kB kinase (IKK) com-
plex, (3) translocation of stress-activated transcription factors
such as p53 and signal transducer and activator of transcription
3 (STAT3) from the cytoplasm to the nucleus, and (4) release of212 Immunity 39, August 22, 2013 ª2013 Elsevier Inc.the chromatin-binding factor high-mobility group box 1
(HMGB1) into the cytosol (Criollo et al., 2011; Kroemer et al.,
2010; Shen et al., 2012; Tang et al., 2012). Conversely, the supply
of autophagic substrates is increased by ubiquitination of
damaged organelles (such as mitochondria, which can be ubiq-
uitinated by parkin) or protein aggregates. Moreover, the affinity
of the adaptors that bridge ubiquitinated proteins to LC3, the so-
called sequestosome 1 (SQSTM1)-like receptors (SLRs), for their
substrate can increase in response to phosphorylation by TANK-
binding kinase 1 (TBK1), as shown for SQSTM1 (best known
as p62) and optineurin (Pilli et al., 2012; Wild et al., 2011). In
this context, any increase in the autophagic demand stimulates
the preferential consumption of supplied substrates, thus prefer-
entially ridding the cells of damaged organelles or protein aggre-
gates.
One major connection between autophagy and other stress-
response pathways is determined by the subcellular structure
at which phagophores form. This structure is in the close prox-
imity of (or corresponds to) so-called mitochondria-associated
ERmembranes (MAMs), sites of anatomical and functional inter-
connection between mitochondria and the ER (Hamasaki et al.,
2013). MAMs are required for nutrient-deprivation-induced auto-
phagy in mammalian cells, presumably as a result of the ability
of the ER protein syntaxin 17 to bind ATG14 and initiate the
recruitment of the ATG5-ATG12 complex and several other com-
ponents of the autophagic machinery, including ATG16L1 (Ha-
masaki et al., 2013; Lei et al., 2012). In addition, MAMs constitute
a preferential location for lipid metabolism (including the gener-
ation of phosphatidylethanolamine, the lipid that is conjugated
to LC3 during autophagy), the regulation of mitochondrial mem-
brane dynamics (fusion and fission), Ca2+ signaling, and the
execution of lethal molecular cascades culminating either in
mitochondrial membrane permeabilization or local caspase-8
activation (Chan, 2012; Iwasawa et al., 2011). At MAMs, multiple
immune-relevant signal transducers physically interact. These
include supramolecular complexes organized around the NLR
family; pyrin domain containing 3 (NLRP3) inflammasome (a plat-
form for the activation of proinflammatory caspase-1) (Subrama-
nian et al., 2013; Zitvogel et al., 2012), mitochondrial antiviral
signaling (MAVS), which interacts with other mitochondrial pro-
teins, such as NLR family member X1 (NLRX1) and Tu translation
elongation factor (TUFM); sensors of viral RNA, such as retinoic
acid inducible gene I (RIG-I) and melanoma differentiation-asso-
ciated protein 5 (MDA5); and stimulator of interferon genes
(STING) (Galluzzi et al., 2012a). These interactions are important
for the elicitation of both innate and adaptive immune responses.
The activation of cell death also represents a mechanism of
adaptation to stress because it preserves organismal homeosta-
sis once cellular damage is irreparable (Fuchs and Steller, 2011).
Some cell-death events are accompanied by a massive auto-
phagic response, a circumstance referred to "autophagic cell
death" (Galluzzi et al., 2012b). However, autophagy often is a
cytoprotective, rather than a cytotoxic, mechanism, thus
reducing the propensity of stressed cells to die (Maiuri et al.,
2007). Conversely, lethal activation of caspases and other prote-
ases (e.g., calpains) results in the digestion of several essential
mediators of autophagy, including BECN1 and ATG5, hence in-
activating the autophagic machinery (Djavaheri-Mergny et al.,
2010; Yousefi et al., 2006). Hence, the autophagic and the
Figure 1. Autophagy, Xenophagy,
Virophagy and LC3-Associated
Phagocytosis in the Control of Intracellular
Pathogens
(A) Autophagy. Specific ribosomal components
and ubiquitinated cytosolic proteins can be deliv-
ered by p62 or other sequestosome 1 (SQSTM1)-
like receptors (SLRs) to autolysosomes, where
they are converted into antimicrobial peptides.
These peptides operate as endogenous antibi-
otics upon the fusion of autolysosomes with bac-
teria-containing phagosomes. Abbreviations are
as follows: LC3-II, lipidated LC3; andUb, ubiquitin.
(B) Xenophagy. Microbe-associated molecular
patterns (MAMPs) or damage-associated molec-
ular patterns (DAMPs) engage surface or intra-
cellular pattern-recognition receptors (PRRs) and
hence activate the autophagic machinery, which
targets intracellular pathogens for lysosomal
degradation. Abbreviations are as follows: AGER,
advanced glycosylation end product-specific re-
ceptor; ALR, AIM2-like receptor; BECN1, Beclin 1;
NLR, NOD-like receptor; RLR, RIG-I-like receptor;
and TLR, Toll-like receptor.
(C) Virophagy. Viruses hijack the hostmachinery to
synthesize nucleic acids (DNA or RNA) and other
components that are required for the assembly of
new viral particles. Such neosynthesized viral
components can be recognized by various SLRs
and directed to lysosomal degradation.
(D) LC3-associated phagocytosis. Phagocytic
vesicles that contain internalized pathogens as
well as dead or live cells can be transiently deco-
rated with LC3. Upon the vessicles’ fusion with
lysosomes, the cargo of these single-membraned
organelles is degraded. Abbreviations are as fol-
lows: CLEC7A, C-type lectin domain family 7,
member A; PI3K, phosphoinositide-3-kinase; PS,
phosphatidylserine; and TIMD4, T cell immuno-
globulin and mucin domain containing 4.
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Reviewapoptotic programs appear to inhibit each other (Galluzzi et al.,
2008b), presumably reflecting the fact that the former generally
attempts to recover cellular, as opposed to organismal, homeo-
stasis. Aging is frequently accompanied by a general autophagy
defect that is commensurate with the reduced capacity of aged
organisms to adapt to stress (Lo´pez-Otı´n et al., 2013). Several
maneuvers that reinstate normal function of the autophagic
machinery, such as the administration of the mTOR inhibitor
rapamycin, might actually decelerate the acquisition of a senes-
cent phenotype (Harrison et al., 2009).
Autophagy, Xenophagy, Virophagy, and Phagocytosis
By definition, autophagy degrades endogenous components of
the cell. In addition, the autophagic pathway or parts of it have
been integrated in defense mechanisms that control invading
pathogens.
Autophagic vacuoles that contain antimicrobial peptidesarising
from the degradation of initially innocuous cytoplasmic proteins,
such as ubiquitin and ribosomal precursor proteins, can fuse
with phagosomes containing bacteria, such as Mycobacterium
tuberculosis, and kill them (Ponpuak et al., 2010). In this context,
autophagy can be viewed as a process that generates endoge-
nous antibiotics to combat invading pathogens (Figure 1A).
In addition, intracellular bacteria can be marked by cellular
ubiquitinases for autophagic degradation, a process that isreferred to as "xenophagy" (Figure 1B) (Levine, 2005). Xeno-
phagy requires all the molecules that are involved in classical
autophagy; in this setting, these molecules orchestrate the
recognition, capture, and elimination of intracellular pathogens.
In the course of infection, autophagy can be stimulated by prom-
inent pattern-recognition receptors (PRRs), including SLRs, Toll-
like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like
receptors (RLRs), and absent in melanoma 2 (AIM2)-like recep-
tors (ALRs). It can also be stimulated by pathogen receptors
such as CD46, as well as by advanced glycosylation-end-prod-
uct-specific receptor (AGER, best known as receptor for
advanced glycosylation end products, RAGE), which together
detect a large panel of microbe-associated and danger-associ-
ated molecular patterns (MAMPs and DAMPs, respectively) (De-
retic, 2011; Tang et al., 2012).
Thanks to one or several LIRs, SLRs act as autophagic adap-
tors between ubiquitin tags onmicrobial (or endogenous) targets
and Atg8 paralogs such as LC3 itself andGABAA-receptor-asso-
ciated protein (GABARAP), thus bringing autophagic cargoes
to nascent autophagosomes. SLRs include p62, optineurin,
neighbor of BRCA1 gene 1 (NBR1), and nuclear dot protein of
52 kDa (NDP52) (Deretic, 2012a). The affinity of SLRs for distinct
types of ubiquitin chains, nonubiquitinated proteins, and Atg8
paralogs varies, a fact that may explain why SLRs differ in their
specificity for invading pathogens. Indeed, whereas bothImmunity 39, August 22, 2013 ª2013 Elsevier Inc. 213
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(Thurston et al., 2009), only the latter mediates the elimination of
Sindbis virus (Orvedahl et al., 2010; Thurston et al., 2009).
Autophagy can also target individual viral components for
degradation, a process termed "virophagy" (Figure 1C) (Orve-
dahl et al., 2011). Virophagy differs from xenophagy in that it tar-
gets neosynthesized viral components rather than entire viral
particles as xenophagy does (usually shortly after endocytosis).
For instance, p62 has been shown to recognize (and send to
degradation) the Sindbis virus capsid in an ubiquitination-inde-
pendent fashion. Globally, it appears that viral proteins and
RNA-protein complexes can be targeted by distinct host factors
for autophagic degradation.
Finally, single-membraned phagocytic vesicles that contain
engulfed bacteria can be transiently decorated with LC3. This
process, which is referred to as "LC3-associated phagocytosis"
(LAP), never results in the formation of double-membraned ves-
icles and depends on both the PI3K complex and the LC3 conju-
gation system but not on the ULK1 complex, underscoring
its biochemical and functional distinction from autophagy
(Figure 1D) (Sanjuan et al., 2007). LAP is important in order for
macrophages to clear invading Burkholderia pseudomallei, the
causative agent of melioidosis (Gong et al., 2011). In addition,
LAP is involved in the degradation of dead cells and the presen-
tation of fungal antigens by macrophages downstream of the
recognition of such entities by T cell immunoglobulin and
mucin-domain-containing 4 (TIMD4, best known as TIM4) or
C-type lectin domain family 7, member A (CLEC7A, also known
as dectin 1), respectively (Ma et al., 2012; Martinez et al., 2011).
The internalization of live cells by other cells of the same type, a
process called entosis, also involves the transient translocation
of LC3 to the engulfing vacuole (Florey et al., 2011), suggesting
that entosis—whose relevance as a bona fide cell death remains
debated (Galluzzi et al., 2012b)—might constitute a special case
of LAP. Of note, BECN1 controls the very first steps of the inter-
nalization of apoptotic cells as it localizes to early phagocytic
cups together with the small GTPase RAC1, with which it inter-
acts (Konishi et al., 2012). Thus, autophagy-relevant proteins
might control the engulfment of cell corpses through an addi-
tional mechanism. Overall, LAP exemplifies a biological process
that is distinct from, but related to, autophagy and that involves
multiple components of the autophagic machinery.
Altogether, these observations exemplify the importance of
autophagy for the cell-intrinsic control of invading microbes.
As discussed below, autophagy also plays a key role in the regu-
lation of cellular immune responses.
Soluble Mediators and Autophagy
Although autophagy constitutes a cell-autonomous mechanism
for the control of noninfectious stress and microbial pathogens,
multiple soluble factors stimulate or inhibit autophagic re-
sponses within cell populations, hence assuring their spatial
and temporal coordination. In addition, the production of cyto-
kines is modulated by autophagy. This mutual relationship un-
derpins multiple mechanisms through which the cell-intrinsic
regulation of autophagy is connected to cell-extrinsic stress-
response pathways (Figure 2).
One primordial response to viral infection is the secretion of
type 1 interferons (IFNs), a series of partially redundant and pleio-214 Immunity 39, August 22, 2013 ª2013 Elsevier Inc.tropic cytokines that act on the IFN (a, b, and u) receptor 1 (IF-
NAR1). Type 1 IFNs stimulate autophagic responses in several
cell lines (Schmeisser et al., 2013). Other soluble mediators
that promote autophagy include the TH1 cytokines tumor necro-
sis factor a (TNF-a) and IFN-g, the pro-inflammatory factor inter-
leukin (IL)-1b, and a large panel of DAMPs, such as HMGB1,
S100 proteins, ATP and histone-DNA complexes. These signals
are perceived by specific cytokine receptors or by a series of
extracellular or intracellular PRRs including TLRs, AGER, puri-
nergic P2RX7 receptors, and AIM2 (Deretic, 2011; Tang et al.,
2012). In sharp contrast, TH2 cytokines, including IL-4 and IL-
13, as well as the anti-inflammatory mediator IL-10, inhibit auto-
phagy (Su et al., 2012). Because DAMPs and cytokines operate
in a spatially and temporally restricted fashion (Zitvogel et al.,
2010), these observations suggest that autophagy is regulated
by soluble mediators in a context-dependent fashion
(Figure 2A). Nonetheless, it is tempting to correlate the TH1/
TH2 polarization of immune responses to the autophagy-medi-
ated control of mycobacteria, a process that appears to be
favored by TH1 and to be inhibited by TH2 cytokines (Doherty,
2012). Moreover, autophagy is stimulated by multiple cell-
death-associated DAMPs, perhaps with the scope of promoting
adaptive responses (and hence minimizing cellular demise) and
stimulating innate immune effectors in tissue areas adjacent to
where cells are dying.
Autophagy favors the release of several proteins, including
cytokines, through processes of "unconventional" secretion
(i.e., the delivery of cytosolic proteins to the extracellular milieu
via amechanism that does not rely on the conventional secretory
pathway’s proceeding through the Golgi apparatus) (Figure 2B).
These proteins include acyl-CoA-binding protein (ACBP) (Bruns
et al., 2011), HMGB1 (Thorburn et al., 2009), and—at least
under specific (and presumably transient) circumstances—IL-
1b and IL-18 (Jiang et al., 2013). Conversely, autophagy limits
the secretion of proinflammatory cytokines, notably IL-1b, by
virtue of its capacity to dampen the activation of the inflam-
masome (Nakahira et al., 2011). This could reflect the ability of
autophagy to remove damaged mitochondria, which release
inflammasome activators such as reactive oxygen species
(ROS) and mitochondrial DNA (mtDNA) (Nakahira et al., 2011;
Zhou et al., 2011), and/or to target ubiquitinated AIM2 and
NLRP3 inflammasomes for destruction (Shi et al., 2012). More-
over, at least in macrophages and DCs, autophagy controls IL-
1b secretion by mediating the degradation of pro-IL-1b (Harris
et al., 2011). Of note, autophagy-related processes such as
LAP can also regulate cytokine production. In the absence of
LAP, the engulfment of dead cells by macrophages is accompa-
nied by an increased secretion of proinflammatory cytokines
such as IL-1b and IL-6, as well as by a decreased production
of anti-inflammatory mediators such as IL-10 and TGF-b (Marti-
nez et al., 2011). Beyond its negative impact on the secretion of
some cytokines, autophagy might exert additional anti-inflam-
matory actions by negatively regulating RLRs (Jounai et al.,
2007). This effect could involve the autophagy-mediated elimina-
tion of ROS-producing mitochondria (Tal et al., 2009), as well as
direct interactions between the ATG5-ATG12 conjugate or
ATG16L1 with the mitochondrial proteins NLRX1 and TUFM,
which operate in RLR-ignited signal transduction pathways (Lei
et al., 2012).
Figure 2. Connection between Extracellular Mediators and Autophagy
(A) Impact of extracellular mediators on autophagy. The binding of various damage-associated molecular patterns (DAMPs) to pattern-recognition receptors
(PRRs) stimulates autophagy. High-mobility group box 1 (HMGB1) and S100 proteins, upon binding to advanced glycosylation-end-product-specific receptor
(AGER), can either reduce the phosphorylation of mammalian target of rapamycin (mTOR, the main negative regulator of autophagy) or activate AMP-activated
protein kinase (AMPK), which in turn inhibits mTOR and activates Unc-51-like kinase 1 (ULK1), a key initiator of the autophagic flux. HMGB1 and S100 proteins
also induce autophagy by dissociating Beclin 1 (BECN1) from inhibitory interactions with BCL-2 and BCL-XL or by signaling via the Toll-like receptor (TLR)
adaptors myeloid differentiation primary response gene 88 (MYD88) or TIR-domain-containing adaptor-inducing interferon-b (TRIF). The detection of extra-
cellular ATP and foreign double-stranded DNA (dsDNA) by the purinergic receptor P2RX7 and DNA sensor absent in melanoma 2 (AIM2), respectively, activates
the inflammasome, which in turn can stimulate the formation of autophagosomes via a signaling cascade involving the small GTPase RAS-like protein B (RALB),
ULK1, and BECN1. Interferon (IFN)-g induces autophagy via immunity-related GTPases (IRGs), whereas tumor necrosis factor a (TNF-a) does so via an
extracellular signal-regulated kinase (ERK)-dependent signaling pathway or through the generation of reactive oxygen species (ROS), which facilitate the ATG4-
dependent lipidation of LC3. Interleukin (IL-1)a/b and IFN-a/b also stimulate autophagy, although the underlying mechanisms remain to be fully elucidated.
Conversely, IL-4, IL-10, and IL-13 exert autophagy-suppressive functions by stimulating an insulin receptor substrate 1 (IRS1)- or phosphoinositide-3-kinase
(PI3K)- dependent pathway leading to the AKT1-mediated activation of mammalian target of rapamycin (mTOR). Alternatively, the autophagy inhibitory effects of
IL-4, IL-10, and IL-13 depend on signal transducer and activator of transcription 3 (STAT3) and STAT6, which disrupt the inhibitory interaction between BECN1
and either BCL-2 or BCL-XL. Extracellular factors exerting autophagy-stimulating or autophagy-inhibiting effects have been labeled in red and green, respec-
tively. Abbreviations are as follows: IFNAR1, IFN (a, b and u) receptor 1; IFNGR1, IFN-g receptor 1; and TNFR1, TNF receptor 1.
(B) Effects of autophagy on cytokine secretion. By removing damagedmitochondria, which otherwise would release inflammasome activators including ROS and
mitochondrial DNA (mtDNA), autophagy limits the secretion of mature IL-1b and IL-18. Moreover, autophagy appears to target assembled inflammasomes for
degradation. Mitochondrial NLR family member X1 (NLRX1) inhibits the RIG-I-like receptor (RLR)-dependent production of type I IFN but promotes autophagy by
interacting with the ATG5-ATG12 complex or with ATG16L1 via its binding partner, Tu translation elongation factor (TUFM). Autophagy controls the secretion of
various other soluble factors via Golgi reassembly and stacking proteins (GRASPs) and the RAS-related protein RAB8A. Along similar lines, the LC3-associated
phagocytosis (LAP) of dead cells engulfed though T cell immunoglobulin and mucin-domain-containing 4 (TIMD4) modulates the release of several cytokines,
including IL-1b, IL-6, IL-10, and transforming growth factor b (TGF-b). Abbreviations are as follows: AIM2, absent in melanoma 2; CASP1, caspase-1; NLRP3,
NLR family, pyrin domain containing 3; PS, phosphatidylserine; PYCARD, PYD and CARD domain containing; and Ub, ubiquitin.
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local induction of autophagy as coordinated by cytokines or
DAMPs is part of a negative-feedback loop that restrains the
excessive generation of proinflammatory factors.
Autophagy in Antigen-Donor Cells
Although it contributes to the cell-autonomous lines of defense
against pathogens, autophagy can also stimulate immune
responses against microbe- or tumor-associated antigens,
especially if ADCs die. Conceptually, this might constitute a
major checkpoint (Figure 3A). Autophagic responses that are
not ensued by cell death are likely to privilege self-limiting, cell-
autonomous defense mechanisms. Conversely, when auto-
phagy is unable to re-establish homeostasis and is followed by
cell death, an immune response is elicited. There are multiple
mechanisms whereby premortem autophagy can influence thepropensity of ADCs or portions thereof to be engulfed by APCs
for presentation to T cells in a productive fashion (Figure 3B).
First, at least in the context of developmental cell death, auto-
phagy appears to increase the emission of potent chemotactic
"find-me" signals, such as ATP and lysophosphatidylcholine
(Elliott et al., 2009; Lauber et al., 2003; Ma et al., 2013), as well
as the exposure of phagocytic "eat-me" signals, such as phos-
phatidylserine (Fadok et al., 2000), on the plasma membrane.
Through these chemotactic and phagocytic cues, premortem
autophagy facilitates the heterophagic clearance of apoptotic
corpses by neighboring cells and thus prevents inflammatory
reactions (Qu et al., 2007). In line with this notion, embryonic
tissues of both Atg5/ and Becn1+/ mice, which exhibit low
intracellular ATP amounts that can be reversed by the provision
of the metabolic substrate methylpyruvate, manifest an inflam-
matory response that is driven by the accumulation of cellImmunity 39, August 22, 2013 ª2013 Elsevier Inc. 215
Figure 3. Impact of Autophagy on Antigen Donor Cells
(A) The life/death switch. In response to stressful conditions, including nutrient deprivation, growth-factor withdrawal, pathogen invasion, mechanical damage,
oncogenic transformation, and exposure to chemotherapeutic agents or radiotherapy, autophagy is activated as a means of reestablishing cellular homeostasis
and preventing inflammatory or immune responses. However, when stress conditions are too harsh or prolonged, the autophagic machinery is overwhelmed and
thus fails to reestablish homeostasis. In this setting, the death of antigen donor cells (ADCs) is inevitable and is accompanied by the elicitation of inflammatory or
immune responses.
(B) Autophagy in ADCs and its impact on immune responses. Premortem autophagic responses in ADCs enhance the release of "find-me" signals, such as ATP
and lysophosphatidylcholine (LPC), as well as of "eat me" signals, such as calreticulin (CRT) and phosphatidylserine (PS), which attract antigen-presenting cell
(APC) progenitors and facilitate antigen uptake, respectively. ATP also stimulates the local differentiation of APCs as well as the activation of their inflammasome,
resulting in the secretion of interleukin-1b. Dying ADCs can also release intact autophagosomes that contain not only multiple antigens but also heat-shock
proteins (HSPs), CRT, high-mobility group box 1 (HMGB1), and defective ribosomal initiation products (DRiPs). Because C-type lectin domain family 9, member A
(CLEC9A) ligand (CLEC9AL) is expressedon their surface, autophagosomes can be taken up by APCs, resulting in the crosspresentation of their antigenic cargo.
Abbreviations are as follows: GPR132, G protein-coupled receptor 132; and PANX1, pannexin 1.
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also required for the optimal release of ATP by dying cancer cells
(Michaud et al., 2011). In this context, autophagy participates in
the trafficking of ATP from specific intracellular compartments
that bear lysosomal markers to a hitherto undefined secretory
compartment, and caspase-dependent, pannexin 1-mediated
secretion of ATP into the extracellular milieu then follows during
the blebbing phase of apoptosis (Chekeni et al., 2010; Martins
et al., 2013). Autophagy-deficient malignant cells, which fail to
release ATP in response to chemotherapy, are unable to recruit
myeloid cells into the tumor bed and hence cannot elicit an anti-
cancer immune response. This defect can be reversed by ecto-
ATPase inhibitors, preserving extracellular ATP levels and hence
allowing for the recruitment of successive waves of myeloid and
lymphoid cells into the tumor in response to chemotherapy (Ma
et al., 2013). Such an ATP-driven chemotactic response requires
the expression of metabotropic P2Y2 receptors on immune cells216 Immunity 39, August 22, 2013 ª2013 Elsevier Inc.(Elliott et al., 2009; Ma et al., 2013). In addition, extracellular ATP
not only can stimulate granulocyte myeloid precursors to differ-
entiate into inflammatory DCs rather than into neutrophil granu-
locytes (the default pathway) (Michaud et al., 2011) but also can
bind ionotropic P2RX7 receptors on DCs, and thereby stimulate
them to secrete IL-1b (Ghiringhelli et al., 2009).
Second, antigen-sequestering autophagosomes can be
directly transferred from cell corpses to DCs for optimal cross-
presentation. These organelles are particularly efficient at stimu-
lating specific immune responses if they are purified from cells
that are treated with proteasome inhibitors because this in-
creases the p62-dependent uptake of various autophagosomal
substrates (Twitty et al., 2011). Indeed, purified autophago-
somes harbor not only long-lived proteins but also short-lived
polypeptides, including defective ribosomal initiation products
(DRiPs) and several DAMPs, such as calreticulin (CRT) and
heat-shock proteins (Li et al., 2011). The cross-presentation of
Figure 4. Impact of Autophagy on Antigen-
Presenting Cells
(A) Toll-like receptors (TLRs). Natural or synthetic
TLR ligands can be sequestered in autophago-
somes, which facilitate the binding of cognate
endosomal TLRs. This process can stimulate the
secretion of type I interferon (IFN) and thus
enhance antigen presentation. Abbreviations are
as follows: IRF7, IFN-regulatory factor 7; MYD88,
myeloid differentiation primary response 88; and
pDC, plasmacytoid dendritic cell.
(B) MHC class II presentation. Extracellular anti-
gens captured by APCs are delivered to auto-
phagosomes, which utilize hydrolases from
endosomes (such as cathepsins) to generate
immunogenic peptides and load them onto MHC
class II molecules for presentation to CD4+ T cells.
Ii, invariant chain; MIIC, MHC class II loading
compartment.
(C) Immunological synapse. The formation of an IS
between APCs and T lymphocytes leads to the
activation of serine threonine kinase 11 (STK11)
and AMP-activated protein kinase (AMPK), which
inhibit mammalian target of rapamycin and hence
stimulate autophagy. In this setting, autophago-
somes are oriented toward the IS and degrade
synaptic components, eventually destabilizing
it and inhibiting T cell activation. Abbreviations
are as follows: ICAM1, intercellular adhesion
molecule 1; ITGB2, integrin, b2; and TCR, T cell
receptor.
(D) Amphisomes. Intracellular antigens engulfed
in autophagosomes can be digested sequen-
tially by amphisomes (formed upon the fusion
of autophagosomes with endosomes) and
proteasomes. The degradation products of
proteasomes can be transported back into
amphisomes by transporter associated with
antigen processing (TAP) and hence loaded
onto recycling MHC class I molecules for antigen
presentation to CD8+ T cells. Alternatively, lysosomal hydrolases can digest intracellular antigens independently of proteasomes. These peptides
are loaded onto recycling MHC class I molecules (and hence presented to CD8+ T cells) independently of TAP.
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action between the C-type lectin domain family 9, member A
(CLEC9A) ligand, which is expressed on the surface of autopha-
gosomes, and CLEC9A (also known as DNGR-1) on DCs, as we
well as on the caveolae-mediated endocytic pathway, which
routes antigens to nonacidic compartments (Li et al., 2011). Of
note, purified autophagosomes can also induce the activation
of B cells in a TLR2- andmyeloid differentiation primary response
88 (MYD88)-dependent fashion (Li et al., 2013). Although the
purification of autophagosomes might yield vaccines that are
more efficient than whole-cell lysates, it is not clear whether
the transfer of such organelles from dying cells to APCs naturally
occurs in vivo, for instance in the context of antimicrobial or anti-
cancer immune responses.
Thus, autophagic responses in virus-infected or transformed
ADCs favor the engulfment and presentation of antigens by
APCs (Michaud et al., 2011; Twitty et al., 2011; Uhl et al., 2009)
(Figure 3B). The pharmacological induction of autophagy can
be exploited as an adjuvant strategy to invigorate anticancer
immune responses (Li et al., 2012).
Autophagy in Antigen-Presenting Cells
Basal autophagic activity is elevated in conventional DCs as
compared with other cell types. Through a variety of mecha-
nisms, this might contribute to the processing of intracellularand extracellular antigens toward MHC-class-I- or -II-restricted
presentation.
Autophagy plays an important role in facilitating the recogni-
tion of intracellular danger signals such as MAMPs by APCs,
thus allowing bacterial, viral, or pharmaceutical adjuvants to
stimulate antigen presentation (Figure 4A). Autophagy can shut-
tle cytosolic MAMPs to the lumen of endosomes, where they can
interact with the ligand-binding domain of TLRs, as demon-
strated for TLR7 and TLR9 ligands (Deretic, 2012b). In line with
this notion, Atg5/ plasmacytoid DCs fail to detect the vesicular
stomatitis virus via TLR7 or the herpes simplex virus 1 via TLR9
and hence fail to produce IFN-a in response to these pathogens
(Lee et al., 2007). Similarly, Atg7/ plasmacytoid DCs fail to
activate IFN-regulatory factor 7 (IRF7) and to produce IFN-a in
response to DNA-containing immune complexes that stimulate
TLR9. However, this effectmight relate to LAP rather than to con-
ventional autophagy because it was not influenced by the
absence of ULK1 (Henault et al., 2012).
Autophagy also plays a major role in the presentation of a sub-
class of MHC-class-II-restricted peptides (Figure 4B). The stim-
ulation of autophagy promotes the display of peptides derived
from cytosolic, mitochondrial, or nuclear (as opposed to mem-
branous) sources, suggesting that the autophagic trafficking
facilitates their access to the MHC class II loading compartment
(MIIC), which is composed of acidic endosomes containingImmunity 39, August 22, 2013 ª2013 Elsevier Inc. 217
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autophagy known as endosome-mediated autophagy prevails
in DCs. In this setting, autophagosomes emerge from MIICs
and bear both the molecular machinery for antigen presentation
and autophagosomal markers such as LC3 and ATG16L1.
Endosome-mediated autophagy may be responsible for the
engulfment of DC aggresome-like lipopolysaccharide-induced
structures (DALISs), which are marked by ubiquitin and p62
(Kondylis et al., 2013). Atg5/ DCs are impaired in their ability
to present soluble and cell-associated antigens on MHC class
II molecules, and they thus trigger suboptimal CD4+ T cell
responses against herpes simplex virus type 2 components
(Lee et al., 2010). Moreover, the presentation of citrullinated pep-
tides on MHC class II molecules depends on ATG5 expression
and can be inhibited by the PI3K inhibitor 3-methyladenine
(Ireland and Unanue, 2011). This process could be relevant to
the pathogenesis of rheumatoid arthritis, in which citrullinated
self-antigens are prominent (Klareskog et al., 2008). Studies in
which Atg5/ thymi were transplanted into wild-type recipients
illustrate that autophagy is required for the MHC-class-II-
restricted presentation of some peptides involved in the positive
and negative selection of CD4+ T cells (Nedjic et al., 2008). Thus,
in thymic medullary epithelial cells, self-antigens gain access to
MHC class II presentation at least in part via autophagy, and this
process assists T cell selection. The requirement for autophagy
in the course of thymic selection is particularly strong for scarce
antigens and for antigens that access the autophagic compart-
ment (but not for plasma membrane proteins) (Aichinger et al.,
2013). It is not clear whether similar observations apply to anti-
gen presentation by peripheral DCs.
When DCs form conjugates with T cells, their autophago-
somes are oriented toward the immunological synapse second-
ary to the activation of AMPK by serine threonine kinase 11
(STK11, best known as liver kinase B1, LKB1) (Figure 4C) (Wild-
enberg et al., 2012). The inhibition of autophagy in DCs by the
RNA-interference (RNAi)-mediated depletion of ATG16L1 or
immunity-related GTPase family M (IRGM) increases the dura-
tion of the synaptic interaction between DCs and T cells, hence
stimulating T cell activation while favoring the generation of TH17
responses (Wildenberg et al., 2012). These results suggest that
autophagy might impinge on the dialog between APCs and
T cells, although they do not unravel themechanisms that under-
lie this phenomenon.
Autophagy might also contribute to the cross-presentation of
MHC-class-I-restricted antigens, mainly because it participates
in the intracellular trafficking and handling of microbial compo-
nents (Figure 4D). For example, DCs control chlamydial infec-
tions within small inclusions that disintegrate uponDC activation,
allowing for the release of bacteria into the cytosol. These cyto-
solic bacteria are then captured by autophagosomes and
degraded upon the recruitment of cathepsin-containing amphi-
somes. Finally, preprocessed antigens access the cytosol
compartment and are processed by proteasomes, reimported
into the endosomal pathway, and loaded into recycling MHC
class I molecules (Fiegl et al., 2013). In other circumstances,
autophagy can contribute to the generation of microbial pep-
tides that are loaded into recycling MHC class I molecules within
the vacuolar compartment. This pathway does not require the
transporter associated with antigen processing (TAP) complex218 Immunity 39, August 22, 2013 ª2013 Elsevier Inc.or the trimming of antigenic peptides at the N-terminus but
instead relies on the trafficking of newly formedMHC class I pep-
tide complexes through the endocytic pathway to the cell sur-
face (Tey and Khanna, 2012).
Of note, the importance of autophagy for antigen presentation
is not limited to DCs but also extends to other APCs including B
cells and macrophages. For instance, both macrophages and B
cells treated with pharmacological inhibitors of autophagy are
impaired in their ability to present antigens on MHC class II mol-
ecules (Brazil et al., 1997; Nimmerjahn et al., 2003).
In summary, autophagy plays a major role in how antigens
from infected or transformed cells are taken up by APCs,
digested to form peptides that can be loaded onto MHC class I
or II molecules, and finally presented to T cells.
Autophagy in T Lymphocytes
Autophagy is induced in both T and B cells upon stimulation of
their T cell and B cell receptors, respectively. ATG3, ATG5,
and ATG7 are dispensable for the development of thymocytes,
but their absence impairs the survival and proliferation of periph-
eral T cells. (Table 1) (Pua et al., 2007). Thus, ATG3, ATG5, and
ATG7 contribute to mature T cell homeostasis and are essential
for the extra-thymic survival of T lymphocytes. At least in part,
this might reflect the critical role of autophagy in the restriction
of the mitochondrial and ER compartments that accompanies
T cell maturation (Jia et al., 2011; Pua et al., 2009; Stephenson
et al., 2009). Along similar lines, Atg5/ B cell progenitors
exhibit developmental defects at the pro- to pre-B transition,
resulting in a dramatic reduction of peritoneal B-1 B cells (Miller
et al., 2008). Autophagy also appears to be required for the
development and function of plasma cells, thuse impacting not
only cellular but also humoral immune responses (Conway
et al., 2013; Miller et al., 2008). This aspect will not discussed
further here.
Autophagy might be needed to preserve intracellular ATP
concentrations or to supply other metabolic intermediates
(such as lipids) that are required for lymphocyte activation and
proliferation (Altman and Dang, 2012). Nonetheless, there is
some controversy over the actual contribution of autophagy to
the adaptation of T cells to changing metabolic demands.
Most data in this respect have been gathered by knockout of
essential autophagy-related genes during early thymocytic
development, a setting in which T cells accumulate undigested
autophagic substrates, including dysfunctional mitochondria.
Indeed, although the inducible deletion of Atg3 in mature naive
T cells does not augment their mitochondrial mass and does
not compromise their survival, T cells that have lacked Atg3
since thymic development do exhibit an increasedmitochondrial
content and are relatively vulnerable to cell death (Jia and He,
2011). This suggests not only that autophagy plays distinct roles
at different stages of T cell development but also that the short-
and long-term consequences of autophagy must be distin-
guished from each other.
Autophagy is downregulated in T cells from agingmice, aswell
as in circulating CD8+CD57+ senescent cells from healthy human
volunteers, and this downregulation correlates with increased
DNA damage (Phadwal et al., 2012). Thus, aging-associated
defects in autophagy might contribute to the immunosenes-
cence of T cells. Of note, at least in some settings, autophagy
Table 1. Examples of the Critical Role of Autophagy in Immune Cells
Cell Type Manipulation or Genotype Phenotype Reference
Bone-marrow-derived DCs MAP1LC3A-specific siRNA;
Becn1+/
Reduced maturation (MHC class II, CD40,
CD80 and CD86 expression); reduced
production of TNF-a, IL-6, IL-12p40
(Morris et al., 2011)
Monocytes Atg7fl/fl - Vav-Cre Inhibition of CSF1-driven differentiation
into macrophages
(Jacquel et al., 2012)
B lymphocytes Reconstitution with Atg5/ fetal
liver cells; Atg5 fl/fl - Cd19-Cre
Defect in B cell development at the pro-
to pre-B cell transition; absence of
peripheral CD5- B cells
(Miller et al., 2008)
Atg5 fl/fl - Cd19-Cre Reduced differentiation into plasma cells;
deficient production of immunoglobulins
(Pengo et al., 2013)
T lymphocytes Reconstitution with Atg5/
fetal liver cells
Reduced numbers of thymocytes, peripheral T
lymphocytes and B cells Increased death of
mature T cells; reduced proliferation of CD4+
T cells upon TCR stimulation
(Pua et al., 2007)
Atg3fl/fl - ER-Cre plus exposure
of T cells to tamoxifen in vitro;
Atg3fl/fl - Lck-Cre
Defective survival of naive CD4+ and CD8+
T cells as well as expanded mitochondria
and ER
(Jia and He, 2011)
Atg5fl/fl - Lck-Cre and
Atg7fl/fl - Lck-Cre
Defective survival and proliferation of naive
CD4+ and CD8+ T cells as well as increased
mitochondrial mass
(Stephenson et al., 2009)
Atg7fl/fl - ER-Cre plus exposure
of T cells to tamoxifen in vitro
Defective IL-2 and IFN-g production by
helper T cells; reduced proliferation of
helper T cells after stimulation
(Hubbard et al., 2010)
Atg7fl/fl - Lck-Cre Increased mitochondrial content, ROS
production and defective Ca2+ handling;
increased apoptotic death of peripheral
T cells
(Jia et al., 2011)
(Pua et al., 2009)
Atg7fl/fl - Cd4-Cre Increased apoptotic death upon CD3/CD28
crosslinking
(Ch’en et al., 2011)
Becn1fl/fl - Cd4-Cre Increased levels of BIM and pro-caspase-3
and 8; increased apoptosis of CD4+ cells
upon TCR stimulation
(Kovacs et al., 2012)
Pik3c3fl/fl - Cd4-Cre Increased mitochondrial mass and ROS in
naive T cells; reduced survival of naive
T cells
(Willinger and Flavell, 2012)
Abbreviations are as follows: Becn1, Beclin 1; Cre, CSF1, colony-stimulating factor 1; ER, estrogen receptor; IFN, interferon; Ig, immunoglobulin; IL,
interleukin; Lck, lymphocyte protein tyrosine kinase; MAP1LC3A, microtubule-associated protein 1 light chain a; ROS, reactive oxygen species;
siRNA, small interfering RNA; TCR, T cell receptor; and TNF-a, tumor necrosis factor a.
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interfering with the T cell receptor (TCR)-induced stimulation of
the NF-kB signal transduction cascade. This signaling pathway
requires the adaptor protein BCL10, which can be tagged with
K63-linked ubiquitin chains, recognized by p62, and hence
degraded by autophagy (Paul et al., 2012). Thus, autophagy
can avoid the adverse consequences of the unrestricted NF-
kB activation that accompanies immunosenescence.
Autophagy-Related Changes in the Antigenicity of
Target Cells
Because autophagy impacts ADC, APC, and T lymphocyte
functions, it is logical to ask whether and how autophagy affects
the recognition of target cells by cytotoxic effectors. Autophagy
can indeed limit the susceptibility of infected or oncogene-
transformed cells to lysis by cytotoxic T lymphocytes (Akalay
et al., 2013), perhaps reflecting its general cytoprotective func-tions. Beyond this, autophagy has a profound impact on the
breadth of the immunopeptidome, i.e., the ensemble of all anti-
genic peptides that are presented by cell-surface-exposed
MHC class I molecules (Admon and Bassani-Sternberg, 2011).
The potential mechanisms underpinning such an antigenic effect
are manifold.
First, autophagy profoundly affects translation. The induction
of autophagy is accompanied by the phosphorylation of eukary-
otic translation initiation factor 2a (eIF2a), which blocks 50 cap-
dependent translation while favoring that of mRNAs harboring
an internal ribosome entry site (IRES) (Figure 5A) (Thakor and
Holcik, 2012). Along similar lines, autophagy frequently ensues
the inhibition of TORC1 (Laplante and Sabatini, 2012) and hence
mimics rapamycin in its ability to profoundly alter the immuno-
peptidome, leading to the appearance of multiple neoantigens
on the cell surface (Caron et al., 2011). This can be explained
by the fact that TORC1 inhibition causes the dephosphorylationImmunity 39, August 22, 2013 ª2013 Elsevier Inc. 219
Figure 5. Effects of Autophagy on the Immunopeptidome
(A) Consequences of autophagy on protein translation. The induction of autophagy is accompanied by the phosphorylation of eukaryotic translation initiation
factor 2a (eIF2a) and mammalian target of rapamycin complex 1 (mTORC1) inhibition, both of which turn off conventional 50-cap-dependent transcription by
ribosomes. Conversely, the transcription of mRNAs containing internal ribosome entry sites (IRESs) operates independent of 50-cap molecules and is not in-
hibited by autophagy. Abbreviations are as follows: eIF4E, eukaryotic translation initiation factor 4E; eIF4EBP1, eIF4E-binding protein 1; and P-eIF2a, phos-
phorylated eIF2a.
(B) Impact of autophagy on the miRNA core machinery. Two core components of the miRNA-handling machinery, namely, DICER1 and argonaute RNA-induced
signaling complex (RISC) catalytic component 2 (AGO2), are captured by the adaptor nuclear dot protein of 52 kDa (NDP52) and degraded by autophagy. mRNAs
processed by the miRNA-induced RISC (miRISC) are prone to generate defective ribosomal initiation products (DRiPs), which take precedence over full-length
polypeptides as they are loaded onto MHC class I molecules.
(C) DRiP degradation. When autophagy is inhibited, ubiquitinated DRiPs accumulate in aggresome-like-induced structures (ALISs) via a p62-dependent
mechanism, are degraded by proteasomes, and enter the classical transporter-associated with antigen processing (TAP)-dependent MHC class I presentation
pathway. Conversely, when autophagy is operational, ALISs do not form and ubiquitinated DRiPs are either recognized by neighbor of BRCA1 gene 1 (NBR1) and
destined to autophagic degradation or directly processed by proteasomes.
(D) Epitope liberation. Autophagy canmediate the partial degradation of some antigens, thus facilitating their further digestion through proteasomes. This process
is known as "epitope liberation."
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tein 1 (eIF4EBP1, best known as 4E-BP1) and ribosomal protein
S6 kinase 70 kDa polypeptide 1 (RPS6KB1, best known as
p70S6K), both of which are involved in 50 cap-dependent transla-
tion (Ma and Blenis, 2009). Experimentally, it has been possible
to immunize mice against these novel, rapamycin-induced
MHC-class I-restricted peptides and hence to stimulate the
development of cytotoxic T lymphocytes that specifically lyse
rapamycin-treated, but not untreated, lymphoma cells (Caron
et al., 2011). Of note, although it has been proposed that
stress-responsive eIF2a kinases such as PKR might indirectly
activate TORC1 (and thus stimulate translation) (Kazemi et al.,
2007), several authors consider the eIF2a and TORC1 signal
transduction cascades to be largely independent from each
other (Ma and Blenis, 2009).
Second, autophagy can impact the immunopeptidome by
regulating miRNA homeostasis (Figure 5B). NDP52 targets the220 Immunity 39, August 22, 2013 ª2013 Elsevier Inc.miRNA-processing enzyme DICER1 as well as the main effector
of miRNA-dependent silencing, argonaute RISC catalytic
component 2 (AGO2, also known as EIF2C2), for autophagic
destruction (Frankel and Lund, 2012). MHC-class I-associated
peptides preferentially originate from transcripts bearing
miRNA-responsive elements because these are highly suscepti-
ble to fail translation and generate DRiPs (Granados et al., 2012),
and the abundance of distinct miRNAs has a robust effect on the
immunopeptidome.
Third, autophagy directly affects the subcellular fate of DRiPs,
which are ubiquitinated and either processed by proteasomes or
recognized by NBR1 and destined to autophagic degradation
(Figure 5C). In particular, when autophagy is inhibited, DRiPs
accumulate in aggresome-like-induced structures (ALISs) via a
p62-dependent mechanism, are degraded by the proteasome,
and enter the classical MHC class I antigen processing and pre-
sentation pathway. As a consequence, a reduced autophagic
Immunity
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antigen presentation (Wenger et al., 2012).
Fourth, autophagy can directly initiate the degradation of self-
antigens, which are subsequently processed by proteasomes
and presented in the form of MHC-class-I-bound peptides
(Figure 5D). This phenomenon, which has been referred to as
"epitope liberation," might confer unique antigenic properties
to autophagic cells (Demachi-Okamura et al., 2012).
Altogether, these examples illustrate how autophagy-associ-
ated changes can alter the antigenic properties of cells and
hencemodulate their susceptibility to recognition by the immune
system. Although the physiological relevance of these changes
has not been investigated in vivo, autophagy might facilitate
the recognition of stressed cells by T lymphocytes (Caron
et al., 2011). Moreover, the autophagy-associated alterations
of the immunopeptidome might affect antigen presentation by
DCs upon cross-dressing, i.e., the transfer of preloaded MHC
class I molecules from the surface of ADCs to CD8a+ or CD8a-
DCs (Smyth et al., 2012; Wakim and Bevan, 2011).
Immune-Relevant Perturbations of Autophagy
Genetic alterations in autophagy may be hereditary, predispos-
ing individuals to autoimmune, auto-inflammatory, or infectious
diseases. Moreover, autophagy can be inactivated by genetic
or epigenetic events in somatic cells, favoring the escape of
(pre)malignant lesions from immunosurveillance.
Infectious Diseases
Various single-nucleotide polymorphisms (SNPs) or mutations
in genes coding for IFN-inducible GTPases have been linked to
an increased susceptibility to bacterial or viral infections in
humans. These genes include IRGM (which affects the suscep-
tibility to M. tuberculosis and S. enterica serovar typhimurium)
(King et al., 2011), GBP1 and GBP2 (influencing the propensity
to infection by Chlamydia trachomatis, S. enterica serovar typhi-
murium, Lysteria monocytogeneses, and adherent invasive
Escherichia coli) (Kim et al., 2012a), as well as MX1 (affecting
vulnerability to hepatitis B, hepatitis C, measles, and West Nile
viruses) (Bigham et al., 2011; Saito et al., 2004). However,
although autophagy-deficient mice undoubtedly exhibit a pleio-
tropic susceptibility to infectious agents, the link between the
aforementioned genes and autophagy remains elusive. IFN-
inducible GTPases have indeed been postulated to play a broad
role in vesicular trafficking by stimulating not just autophagic but
also oxidative, membranolytic, and inflammasome-related anti-
microbial activities (Kim et al., 2012a).
Systemic Lupus Erythematosus
Genome-wide association studies and meta-analyses have
linked genetic polymorphisms in ATG5 and DRAM1 to the path-
ogenesis of systemic lupus erythematosus (SLE) (Harley et al.,
2008; Yang et al., 2013). However, the functional consequences
of these SNPs on the immune system have not been elucidated
yet. T cells from SLE patients or from two distinct SLE-prone
mouse strains, namely (NZB 3 NZW)F1 and MRL
lpr/lpr mice,
reportedly contain increased amounts of autophagosomes as
compared to T cells from control patients or mice (Gros et al.,
2012). This suggests that SLE might be associated with alter-
ations in the autophagic flux, but the underlying molecular de-
fects have not yet been elucidated. According to one study,
naive CD4+ T cells from SLE patients are resistant to the induc-tion of autophagy by autologous IgGs (Alessandri et al., 2012). Of
note, SNPs in ATG5 (although different from those associated
with SLE) have also been linked to childhood asthma (Martin
et al., 2012), although the underlying molecular mechanisms
remain elusive.
Crohn’s Disease
SNPs in several autophagy-relevant genes (e.g., ATG16L1,
NOD2, and IRGM) influence the pathogenesis of Crohn’s dis-
ease but not that of ulcerative colitis. In particular, ATG16L1
can be affected by an amino acid substitution (T300A) within
its conserved WD repeat domain (Hampe et al., 2007), whereas
NOD2 might carry multiple distinct mutations in its C terminus
(Hampe et al., 2001; Ogura et al., 2001). IRGM can be affected
by at least two alterations that reduce its expression; namely,
these alterations are a 29 Kb deletion upstream of the coding
sequence and a synonymous substitution (c.313C > T) that facil-
itates the interaction of the IRGM-coding mRNA with miR-196,
which is expressed in the intestinal epithelium (Patel and Stap-
penbeck, 2013). NOD2 (as well as its homolog NOD1) can
directly interact with ATG16L and is recruited to the plasma
membrane of intestinal epithelial cells at bacterial entry sites,
from which it channels bacteria to xenophagic degradation
(Travassos et al., 2010). Moreover, NOD2 stimulates autophagy
in DCs, thus favoring the handling of pathogenic bacteria and the
subsequent presentation of bacterial antigens (Cooney et al.,
2010). ATG16L1 loss-of-function mutations that are pathogenic
in the context of inflammatory bowel disease could be advanta-
geous in the context of chronic bladder infection by E. coli. Thus,
the absence of ATG16L1 from bladder epithelial cells or hemato-
poietic cells was sufficient to generate a relative resistance
against uropathogenic E. coli (Wang et al., 2012). In models of
Crohn’s disease, autophagic defects appear to compromise
the antimicrobial defenses of intestinal epithelial cells (in partic-
ular Paneth cells) (Cadwell et al., 2008), to subvert the microbici-
dal function of immune cells, and to lead to an exaggerated
secretion of IL-1b, IL-6, and TNF-a (Lapaquette et al., 2012; Sai-
toh et al., 2008). Although it is tempting to ascribe the proinflam-
matory effects of ATG16L1A197T on the intestinal epithelium to an
autophagic defect, it remains possible that ATG16L1 mutations
affect autophagy-unrelated phenomena. In this respect, an
IFN-g-elicited supramolecular complex involving the ATG5-
ATG12 conjugate and ATG16L1 has been suggested to mediate
antiviral effects independently from the degradative activity of
autophagy (Hwang et al., 2012). Moreover, ATG16L1 reportedly
influences hormone secretion by neuroendocrine cells in an
autophagy-independent fashion (Ishibashi et al., 2012). This sug-
gests (but does not formally demonstrate) that ATG16L1 muta-
tions contribute to the pathophysiology of Crohn’s disease
through pleiotropic effects on multiple cell types.
Cystic Fibrosis
Cystic fibrosis (CF) is caused by mutations in CFTR, encoding
cystic fibrosis transmembrane conductance regulator, and is
the most common inherited lethal disease among Caucasians.
The loss-of-function of CFTR, which is coupled to a progressive
autophagic defect presumably as a result of the sequestration of
BECN1 in perinuclear aggregates (Luciani et al., 2010), culmi-
nates in chronic bacterial infection (and inflammation) of the
lungs. The restoration of autophagy by pharmacological agents
such as cystamine and rapamycin appears to improve theImmunity 39, August 22, 2013 ª2013 Elsevier Inc. 221
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plasmamembrane, at least in the case of themost frequent path-
ogenic CFTR mutation, DF508 (Villella et al., 2013). Moreover,
rapamycin has been shown to exert profound antibacterial and
anti-inflammatory effects in murine models of CF and in
explanted nasal epithelia from CF patients (Abdulrahman et al.,
2011). It remains to be seen whether these preclinical results
can be translated to children affected by CF.
Cancer
From a classical point of view, cancer represents a cell-autono-
mous (epi)genetic disease originating from the accumulation of
driver alterations that (1) are accompanied by a plethora of pas-
senger mutations and (2) are coupled to a high degree of genetic
and phenotypic heterogeneity (Hanahan and Weinberg, 2011).
From an immunological point of view, cancer can only develop
when (pre)malignant cells escape from immunosurveillance by
losing (or altering) their antigenic properties or by actively sup-
pressing antitumor immune responses (Schreiber et al., 2011).
Especially during early oncogenesis, a variety of (epi)genetic
events may inactivate autophagy. These include the loss of het-
erozygosity of BECN1; alterations causing constitutive signaling
viamTOR, such as activatingmutations in the catalytic subunit of
PI3K or the loss of PTEN; the accumulation of mutant p53, and
the overexpression of antiapoptotic proteins from the BCL-2
family (Morselli et al., 2009; White, 2012). This property of incip-
ient cancer lesions favors genomic instability (Mathew et al.,
2007), perhaps as a result of redox alterations (Green et al.,
2011), and might also be tied to the escape of pre(malignant)
cells from immunosurveillance. Autophagy-deficient tumors
indeed fail to elicit anticancer immune responses upon exposure
to chemotherapy, in line with the essential role of autophagy in
the immunogenicity of ADCs (Michaud et al., 2011). It will be
important to investigate how these links apply to bioptic speci-
mens from cancer patients and in particular to search for a cor-
relation between natural or therapy-elicited antitumor immunity
and autophagic responses, which are often reacquired during
tumor progression because they confer to transformed cells an
increased resistance against adverse microenvironmental cues
(Morselli et al., 2009; White, 2012).
Taken together, these observations suggest that the initiation
or progression of various human pathologies with an immuno-
logical component is favored by genetic or epigenetic alterations
that inhibit autophagy.
Concluding Remarks
Undoubtedly, autophagy plays a critical role in cellular immune
responses, in both physiological and pathological settings,
raising major expectations on the therapeutic impact of auto-
phagy-modulatory agents. At this point, however, several recur-
rent problems must be taken into attentive consideration before
firm recommendations can bemade on the therapeutic inhibition
or induction of autophagy.
The conclusion that autophagy is involved in a specific biolog-
ical process is usually based on interventions targeting one
among multiple ATG-coding genes. However, many ATG pro-
teins participate in intracellular trafficking systems beyond auto-
phagy (such systems involve multiple ATG proteins as a module
and include, for instance, phagocytosis, LAP, and entosis) or in
signal-transduction pathways that crosstalk with PRR-elicited222 Immunity 39, August 22, 2013 ª2013 Elsevier Inc.processes (such pathways frequently involve individual ATGpro-
teins). For instance, ATG12 has recently been implicated in both
the maintenance of mitochondrial homeostasis (when it is conju-
gated to ATG3) and mitochondrial apoptosis (Boya et al., 2013;
Radoshevich et al., 2010; Rubinstein et al., 2011). Along similar
lines, ATG7 reportedly binds p53 and thus controls the ability
of the latter to transactivate the gene that encodes cyclin-depen-
dent kinase inhibitor 1A (CDKN1A), a cytoprotective cell cycle
inhibitor (Lee et al., 2012). This implies that (1) unequivocal
cause-effect relationships between autophagy as a pathway
and pathological conditions (or their resolution) have been estab-
lished in a limited number of instances and (2) much of the data
published in this context might have to be reinterpreted in view of
the growing number of autophagy-independent functions attrib-
uted to ATG proteins (Boya et al., 2013). Thanks to proteomic
studies, functional screenings, and robust bioinformatics ana-
lyses, multiple autophagy-unrelated physical interactors of
ATG proteins have begun to emerge (Behrends et al., 2010; He
and Levine, 2010). Further studies, however, are urgently
awaited and will need to elucidate the actual pathophysiological
relevance of these interactions.
The systemic stimulation or suppression of autophagy can
modulate immune responses by affecting ADCs, APCs, or down-
stream effector cells. This might explain why the clinical manifes-
tations of ATG5 mutations that are associated with SLE and
Crohn’s disease in population studies are not so obvious when
studied on a patient-by-patient basis; they affect just a fraction
of individuals, only once sexual maturity has been attained, and
often with an opposite-gender effect. This illustrates the intrinsic
difficulty involved in applying linear reasoning to multifactorial
autoimmune and autoinflammatory diseases that often develop
in a cyclic, nonlinear, and highly context-dependent fashion.
To date, no truly specific modulator of autophagy is broadly
available for experimental or clinical exploration. In spite of
numerous scientific reports claiming the autophagy-suppressive
effects of lysosomotropic molecules such as chloroquine, the
actual specificity of these agents is questionable given that lyso-
somes participate in several cellular processes beyond auto-
phagy. For instance, cloroquine is known to promote lysosomal
membrane permeabilization (which triggers apoptotic or necrotic
cell death in an autophagy-independent fashion) (Kroemer and
Ja¨a¨ttela¨, 2005) and to improve antigen presentation by DCs as
a result of its effects on lysosomal acidification (Accapezzato
et al., 2005). Nonetheless, attractive targets for the development
of autophagy inhibitors are several and include the lipid kinase
phosphatidylinositol 3-kinase, catalytic subunit type 3 (PIK3C3,
best known as VPS34 lipid kinase), the proteolytic enzyme
ATG4, and several conjugation systems (Rubinsztein et al.,
2012). Moreover, agents that can disrupt inhibitory protein-pro-
tein interactions within the BECN1 complex, and thus operate
as autophagy inducers, are being developed (Dai et al., 2013;
Shoji-Kawata et al., 2013). We surmise that the development of
specific autophagy-modulatory drugs will yield invaluable tools
for the investigation of the immunological functions of autophagy.
Notwithstanding these multiple caveats, it is plausible that
the therapeutic effects of several established drugs might be
explained—or at least supported—by their ability to stimulate
autophagy. For instance, it appears that 1a,25-dihydroxychole-
calciferol (vitamin D3) is rate limiting for the autophagic activity
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Reviewof human macrophages and that the external supply of
this compound potently inhibits HIV-1 replication and clears
M. tuberculosis in preclinical models (Fabri et al., 2011). This is
in line with old epidemiological data revealing the positive impact
of UV exposure on the clearance of cutaneous tuberculosis (Van
Der Lugt and Rottier, 1958). Importantly, the successful antimy-
cobacterial drugs isoniazid and pyrazinamide potently induce
autophagy inM. tuberculosis-infected cells, and their antibacte-
rial activity is limited in Atg7-deficient strains of Drosophila
melanogaster (Kim et al., 2012b). Conversely, azithromycin, a
macrolide antibiotic, inhibits autophagy as an unwarranted
side effect and thus predisposes CF patients to mycobacterial
infections (Renna et al., 2011). These observations illustrate the
importance of comprehending the autophagy-modulatory
(side) effects of existing drugs.
Many comorbidities of obesity can be explained by the estab-
lishment of a systemic inflammatory state, a process that at least
in part ismediatedby theactivationof the so-called "metabolic in-
flammasome," which also causes insulin resistance. In response
to fatty acids, a signaling complex comprising PKR, IKK, eIF2a,
and insulin receptor substrate 1 (IRS1) becomes activated, result-
ing in the corollary PKR-dependent activation of ER stress (Naka-
muraet al., 2010), inflammasomes (Luetal., 2012), andautophagy
(Shen et al., 2012). Autophagy acts as a negative regulator of this
interplay, suggesting that measures, such as fasting, that stimu-
late the autophagic flux at the whole-body level might be healthy
because they limit the activation of themetabolic inflammasome.
In thiscontext, it remains tobedeterminedwhether thereexist any
agents that mediate robust anti-inflammatory and health-impro-
voing effects by stimulating autophagy; for example, such agents
might, include AMPK-activating chemicals such as aspirin, met-
formin, andmethotrexate (O’Neill andHardie, 2013),which induce
a state of pseudo-starvation. Nonetheless, given the potent anti-
inflammatory and cytoprotective effects of autophagy and its
critical contribution to both innate and adaptive immunity, mea-
sures that induce autophagy in many cell types might constitute
a means of "sharpening" immune responses. Future studies will
have to elucidate towhich extent and under which circumstances
inducers and inhibitors of autophagy might exert therapeutically
relevant immunomodulatory functions.ACKNOWLEDGMENTS
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